Athersys

Athersys Accounts Payable

Delisted·Oct 1, 2026

The Accounts Payable of Athersys (ATHXQ) as of Nov 20, 2026 is 27.77 M USD. In the previous year, Accounts Payable was 16.90 M USD — a change of 64.29% (higher).

Accounts Payable

27.77 MUSD

YoY

64.29%

Last updated:

Accounts Payable of Athersys is 2022 27.77 M USD. Accounts Payable of Athersys was 2021 16.90 M USD. It decreases by 64.29% higher compared to the previous year.

The Athersys Accounts Payable history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Accounts Payable
Date
Accounts Payable
Jan 1, 2015
2.70 M USD
Jan 1, 2016
4.76 M USD
Jan 1, 2017
4.47 M USD
Jan 1, 2018
9.16 M USD
Jan 1, 2019
10.12 M USD
Jan 1, 2020
13.04 M USD
Jan 1, 2021
16.90 M USD
Jan 1, 2022
27.77 M USD
The Athersys Accounts Payable history
YEARAccounts PayableYoY
27.77 MUSD+64.29%
16.90 MUSD+29.58%
13.04 MUSD+28.92%
10.12 MUSD+10.44%
9.16 MUSD+104.92%
4.47 MUSD-6.09%
4.76 MUSD+76.30%
2.70 MUSD-2.53%
2.77 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Athersys Stock analysis

What does Athersys do? Athersys, Inc. generates revenue through the development and commercialization of its MultiStem (invimestrocel) cell therapy, an allogeneic stem cell product candidate derived from adult bone marrow. The company focuses on late-stage clinical development for critical care, neurological conditions, inflammatory disorders, pulmonary conditions, and cardiovascular disease. Its lead product, MultiStem, is currently in Phase III clinical trials for ischemic stroke under the MASTERS-2 study. Athersys targets medical institutions and healthcare providers seeking innovative treatments for unmet medical needs in multiple disease areas. The company's primary product, MultiStem, is manufactured from human stem cells obtained from adult bone marrow and alternative tissue sources. It is designed to address conditions including critical care indications, neurological disorders, inflammatory and immune disorders, pulmonary conditions, and cardiovascular disease. Athersys conducts Phase III trials for ischemic stroke treatment, aiming to secure regulatory approval for broader market access. Revenue streams are expected to emerge post-approval through therapeutic product sales to hospitals and clinics. Athersys, Inc. operates in the biotechnology sector with a focus on regenerative medicine, leveraging its MultiStem platform to address unmet medical needs. The company's clinical development strategy centers on late-stage trials for ischemic stroke and other conditions, targeting healthcare providers and medical institutions as key customers. Commercialization of MultiStem will likely involve partnerships with healthcare systems for treatment protocols and patient access. Athersys is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Athersys stock

Accounts Payable of Athersys is 27.77 M USD in 2022.

Accounts Payable of Athersys changed from 16.90 M USD to 27.77 M USD, representing a 64.29% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Accounts Payable Athersys since 2006 – with annual values, charts, and detailed analysis.

Accounts payable represents money owed to suppliers for goods and services received. It is a key component of working capital management.

Accounts Payable's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Accounts Payable's Athersys historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Athersys

All Key Metrics — Athersys